US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings

HOUSTON, June 02, 2008 /PRNewswire/ -- Physicians affiliated with the US Oncology Research Network are presenting the results of their clinical research at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) held May 30 - June 3, 2008 in Chicago.

Dr. Joyce O'Shaughnessy of Texas Oncology-Baylor Charles A Sammons Cancer Center, an affiliate of US Oncology, gave an oral presentation on findings from a randomized Phase III trial that studied lapatanib (L) alone and in combination with trastuzumab (T) in patients with HER2+ metastatic breast cancer who progressed on trastuzumab. The research is the largest study of two targeted agents in HER2+ metastatic breast cancer and the first to demonstrate the synergy of lapatanib and trastuzumab in a Phase III setting.

The research found that improved clinical outcome was achieved with the combination of L+T in patients progressing on T-based therapy and without substantial change in the side-effect profile. The role of combined anti-HER2 therapy, in combination with chemotherapy, in less heavily pretreated patients with early stage disease is ongoing in the Adjuvant L and/or T Treatment Optimization (ALTTO) study.

"More complete HER2 blockade with lapatinib and trastuzumab benefits patients whose metastatic breast cancer (MBC) is progressing in spite of trastuzumab therapy," said Dr. O'Shaughnessy. "This combination is an important new therapeutic strategy for HER2+ MBC patients, one that does not contain chemotherapy. This combination also has exciting potential as treatment for early stage breast cancer, a hypothesis that is being evaluated now in the global ALTTO trial." Dr. O'Shaughnessy serves as co-chair of the US Oncology Breast Cancer Research Committee and associate director for clinical research for US Oncology.

In addition to Dr. O'Shaughnessy's presentation, physicians affiliated with US Oncology participated in 23 oral and poster presentations and published studies at this year's ASCO conference. Findings were presented on a variety of disease states including breast, lung, genitourinary, gynecologic, and melanoma.

    Breast

    --  Nicholas Robert, M.D., Fairfax-Northern Virginia Hematology-Oncology,

        co-chair US Oncology Breast Cancer Research Committee: Results of a

        Phase II study of pemetrexed as first-line chemotherapy for advanced

        or metastatic breast cancer

    --  Michael Danso, M.D., Virginia Oncology Associates: Phase II trial of

        weekly administration of nabpaclitaxel in combination with bevacizumab

        in women with metastatic breast cancer (MBC)

    --  Mary Ann Allison, M.D., Comprehensive Cancer Centers of Nevada-Siena

        and Joanne Blum, M.D., Ph.D., Texas Oncology-Baylor Charles A Sammons

        Cancer Center: Phase II study of eribulin mesylate in patients with

        locally advanced or metastatic breast cancer (MBC) previously treated

        with an anthracycline, taxane, and capecitabine

    --  Sasha Vukelja, M.D., Texas Oncology-Tyler: Phase II and Phase III

        study of the efficacy of nab-paclitaxel in patients with poor

        prognostic factors or with anthracycline-resistant metastatic breast

        cancer (MBC)

    --  Frankie Holmes, M.D., Texas Oncology-Houston Memorial City,

        US Oncology network associate chair Breast Cancer Research Committee,:

        Phase II study on transcriptional profiles of triple receptor-negative

        breast cancer: Are Caucasian, Hispanic and African-American different?



    Lung

    --  Charles Weissman, M.D., New York Oncology-Hematology--Latham: Phase

        III open-label comparison of gemcitabine/oxaliplatin versus

        paclitaxel/carboplatin as first-line therapy for advanced non-small

        cell lung cancer (NSCLC)



    Genitourinary

    --  Guru Sonpavde, M.D., Texas Oncology-Deke Slayton Cancer Center: Phase

        II study of Azacitidine for castration-resistant prostate cancer

        progressing on combined androgen blockade

    --  Phillip Periman, M.D., Texas Oncology-Amarillo: Phase II study of

        Sunitinib malate for metastatic castration-resistant prostate cancer

        following docetaxel-based chemotherapy

    --  Allen Cohn, M.D., Rocky Mountain Cancer Centers-Midtown, co-chair,

        US Oncology GI Cancer Research Committee: Phase III Panitumumab (pmab)

        regimen evaluation in colorectal cancer to estimate primary response

        to treatment (PRECEPT): effect of KRAS mutation status on second-line

        treatment (tx) with pmab and FOLFIRI

    --  Thomas Hutson, D.O., PharmD, Texas Oncology-Baylor Charles A Sammons

        Cancer Center, associate chair, US Oncology GU Cancer Research

        Committee,: RAD001 plus best supportive care (BSC) vs BSC plus

        placebo in patients with metastatic renal cell carcinoma (RCC), which

        has progressed on VEGF-TKI therapy: results from a randomized,

        double-blind, multicenter Phase III study; Phase III randomized study

        of overall survival with sunitinib versus interferon (IFN)-alfa as

        first-line treatment of metastatic renal cell carcinoma (mRCC);

        Multicenter, Phase I/II study of sunitinib in combination with

        docetaxel and prednisone in patients with metastatic

        castrate-resistant prostate cancer (mCRPC)-preliminary results;

        Biomarker analysis and final results of a phase II renal cell

        carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis

        inhibitor; A multicenter, prospective Phase II trial of sorafenib in

        patients (Pts) with metastatic clear cell renal cell carcinoma

        (mccRCC) refractory to prior sunitinib or bevacizumab

    --  Kelly Pendergrass, M.D., Kansas City Cancer Center-South:

        Characterization of hyperglycemia, hypercholesterolemia, and

        hyperlipidemia in patients with advanced renal cell carcinoma

        treated with temsirolimus or interferon



    Gynecologic

    --  Michael Teneriello, M.D., Texas Oncology-Austin Central,  co-chair,

        US Oncology Gynecologic Cancer Research Committee: Phase III trial of

        induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C)

        followed by elective T consolidation in advanced ovarian cancer (OC):

        Interim analysis of induction chemotherapy



    Melanoma

    --  William Stephenson, M.D., Kansas City Cancer Center-South: PhaseI/II

        study of imexon (AMP) plus dacarbazine (DTIC) in patients (Pts) with

        metastatic malignant melanoma



    Leukemia

    --  Roger Lyons, M.D., Cancer Care Centers of South Texas-Medical Center:

        Phase II study of single agent clofarabine in previously untreated

        older adult patients with acute myelogenous leukemia (AML) unlikely to

        benefit from standard induction chemotherapy



    Solid Tumors

    --  William Stephenson, M.D., Kansas City Cancer Center-South: Phase I

        study multicenter study to assess the safety, tolerability, and

        pharmacokinetics of AZD4877 administered twice weekly in adult

        patients with advanced solid malignancies

    --  Robert Raju, M.D., Dayton Oncology & Hematology-Kettering: An open

        label Phase I dose escalation study of ADH-1 in combination with

        chemotherapy in subjects with N-Cadherin expressing solid tumors



    Lymphoma and Plasma Cell Disorders

    --  Alan Feiner, M.D., Rocky Mountain Cancer Centers-Rose, and John

        Mattern, D.O., Virginia Oncology Associates-Newport News: Primary

        therapy of Waldenstrom's macroglobulinemia with bortezomib,

        dexamethasone and rituximab: results of WMCTG Clinical Trial 05-180


About US Oncology Research

The US Oncology Research network is an established community-based research operation specializing in all phases of cancer clinical trials. The research network currently has 595 physicians actively enrolling patients, 109 research sites, and is currently involved in 63 open research trials. The network has contributed to the development of 24 of 30 of the latest cancer-fighting drugs approved by the Food and Drug Administration for use. Since 1993, more than 32,000 patients have participated in clinical trials managed by US Oncology network practices. For more information, visit the "Research" section under "Our Services" on the company's Web site, http://www.usoncology.com.

About US Oncology, Inc.

US Oncology, headquartered in Houston, works closely with physicians, manufacturers and payers to identify and deliver innovative services that enhance patient access to advanced cancer care. US Oncology supports one of the nation's foremost cancer treatment and research networks accelerating the availability and use of evidence-based medicine and shared best practices.

US Oncology's expertise in supporting every aspect of the cancer care delivery system -- from drug development to treatment and outcomes measurement, enables the company to help increase the efficiency and safety of cancer care. According to the company's last quarterly earnings report, US Oncology is affiliated with 1,247 physicians operating in 472 locations, including 91 radiation oncology facilities in 39 states. For more information, visit the company's Web site, http://www.usoncology.com.

CONTACT: Lisa Henderson, +1-813-775-6208,, for US Oncology, Inc. Lisa.Henderson@hillandknowlton.com

Web site: http://www.usoncology.com/

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: June 2008

View comments

Hide
(web4)